Experts are worried that a drug, which improves speech in Alzheimer's patients, may trigger false hopes. The popular rheumatoid arthritis drug had shown significant improvement in patients with Alzheimer's in a study appearing in the journal BioMed Central BMC Neurology.
The study involved just 12 patients and hence the Alzheimer's Association has expressed concern.
Advertisement"People with Alzheimer's and their families may place undue value on this new finding based on the dramatic language used in its description and the apparent immediate effect," the group said. "We need to see work in other laboratories by scientists without financial interest in the product."
Dr. Scott Turner, incoming director of the Memory Disorders Program at Georgetown University Medical Center said there must be double-blind, placebo-controlled, randomized clinical trials before any judgment is passed.